Provider review
VevaRX Review: An Honest Compounding Disclosure, With Nobody Named Behind It
VevaRX writes the compounding disclosure most of this market omits — unprompted, on every peptide page, in plain words. Its NAD+ education panel is some of the most careful copy we have read in this category: it describes what the molecule does in a cell rather than what it will do for you. The headlines are louder than the panels, the glutathione page quotes two prices for one plan, and nobody behind the product is named: no pharmacy, no prescriber, no address.
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit VevaRXOf VevaRX’s 5 dated product claims documented below, 1 is consistent with the cited evidence. Comparable upfront pricing is not established here. A matching claim does not mean the compounded product was tested or FDA-approved.
Says the honest thing about compounding that most of this market won't, and names nobody behind the product: no pharmacy, no prescriber, no address.
Worth trusting if
- You want a seller that tells you compounded medicines are not FDA-approved without being asked
- You are buying sermorelin and want a page that promises you no outcome it cannot show
- You read the NAD+ education panel rather than the NAD+ headline
Be skeptical if
- You are buying glutathione and want one price, because its page quotes two
- You want to know which pharmacy compounds your prescription, or who prescribes it, because neither is named
- You want a mailing address, because the refund clause asks you to write to one the site never gives
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at VevaRX
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Sermorelin, three-month plan — $399 for the three-month plan, the same figure on the card, in the plan text and in the billing text, billed every three months.
- NAD+, three-month plan — $399 for the three-month plan, the same figure on the card, in the plan text and in the billing text.
- Glutathione, three-month plan — The card says $349 for the three-month plan, and the NAD+ & Glutathione Stack page uses the same figure when it adds up the two separate prices. The plan text and billing text on the glutathione page say $267.
- PT-141 — $247 a month, or $598 for a three-month plan, which the page gives as the equivalent of $199 a month.
- NAD+ & Glutathione Stack, three-month plan — $699 for the three-month stack, the same figure on the card, in the plan text and in the billing text. The page sets it against $748 for the two plans bought separately, a saving of $49.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
1
Products with human evidence
For the advertised use, out of 5 products reviewed here. The evidence concerns the molecule, not VevaRX's service.
2
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from VevaRX’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Sermorelin, three-month planSermorelin · Compounded (503A)Claim matches the trials
“Sermorelin — Personalized wellness support with licensed provider oversight. Sermorelin is a provider-prescribed peptide therapy offered as part of an individualized treatment plan. Eligibility is determined by a licensed healthcare provider.”
Read on the VevaRX site, September 2026
No trial for this use
What the trials show for Sermorelin
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005. Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None tests energy, recovery, body composition or wellness in healthy adults. A parallel ClinicalTrials.gov search returned 27 studies; the two closest to the marketed use are both phase 2 and both terminated, at 13 and 5 participants.
There is nothing here to correct, because there is no efficacy claim to check. "Personalized wellness support with licensed provider oversight" describes a service — a provider looks at your assessment and decides — and promises no outcome at all. That is genuinely rare: nineteen randomized sermorelin trials exist and none measured what this molecule is usually sold for, so a seller that declines to name an outcome is the only kind that cannot overreach.1
NAD+, three-month planNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“NAD+ — Support Energy, Focus, & Cellular Vitality.”
Read on the VevaRX site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for nicotinamide adenine dinucleotide combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
One page, two voices. The headline promises the buyer energy, focus and cellular vitality; the education panel a few hundred pixels below promises nothing of the kind, saying only that NAD+ "helps support the normal cellular processes involved in converting nutrients into usable energy" and that its role in aging "is being studied … though research is ongoing." The panel is accurate and admirably careful. The headline is the part in large type, and no completed randomized trial of injected NAD+ supports it.2
Glutathione, three-month planGlutathione · Compounded (503A)No trial supports this claim
“Glutathione — Support cellular detoxification, immune function, healthy aging, and reduce inflammation.”
Read on the VevaRX site, September 2026
No trial for this use
What the trials show for Glutathione
As of August 2026, a PubMed search for glutathione in title or abstract, combined with an injected route and with skin, detoxification, fatigue or energy, restricted to the randomized-controlled-trial publication type, returned seven records. Not one tests injected glutathione on its own for any of those outcomes. On ClinicalTrials.gov, 268 studies list glutathione as an intervention; restricting to injected routes returns three, in mantle-cell lymphoma, acute liver failure and pneumonia.
Four outcomes, and the last one is the strongest unhedged claim on the site. "Support" carries the first three; "reduce inflammation" drops the hedge and states a physiological effect flatly. No randomized trial of injected glutathione on its own has measured inflammation, or detoxification, or immune function, or aging. On a site that elsewhere writes with real care about what is and is not known, this sentence is the outlier.3
PT-141Bremelanotide (PT-141) · Compounded (503A)Claim reaches past the trials
“PT-141 — Provider-Guided Support for Sexual Desire.”
Read on the VevaRX site, September 2026
Phase 3 trials
What the trials show for Bremelanotide (PT-141)
- NCT02333071 RECONNECT Study 1 — Phase 3, completed, n=723. Premenopausal women with hypoactive sexual desire disorder. One of the two trials behind the FDA approval of bremelanotide.
- NCT02338960 RECONNECT Study 2 — Phase 3, completed, n=714. The identical second trial, in the same population.
"Support for sexual desire" names exactly the outcome RECONNECT 1 and 2 measured across 1,437 participants, which is more than most sellers of this molecule manage. What it does not name is who those participants were: premenopausal women diagnosed with hypoactive sexual desire disorder. The page is open to any buyer, says nothing about sex or diagnosis, and never mentions that an approved version of this molecule exists.4
NAD+ & Glutathione Stack, three-month planNAD+ and glutathione · Compounded (503A)Claim reaches past the trials
“NAD+ & Glutathione Stack — Cellular Energy + Detox Support, Together in One Plan. […] NAD+ helps support the normal cellular processes involved in converting nutrients into usable energy, focus, and vitality. […] Glutathione participates in the body's normal antioxidant, detoxification, and immune-supporting processes. […] Both therapies are being studied for their roles in healthy aging, though research is ongoing.”
Read on the VevaRX site, September 2026
No trial for this use
As of August 2026, a PubMed search for nicotinamide adenine dinucleotide combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records, and a PubMed search for injected glutathione against skin, detoxification, fatigue or energy outcomes returned seven randomized records, none testing injected glutathione on its own. No trial of the two given together was found.
Most of this page is written with the same care as the NAD+ education panel: glutathione "participates in" normal processes, and the aging research is described as ongoing. Two phrases reach further. The headline sells "Cellular Energy + Detox Support" as an outcome of the plan, and the NAD+ sentence that reads carefully on its own page gains three words here, "focus, and vitality", which describe the person rather than the cell. No randomized trial of injected NAD+ or injected glutathione has measured energy, focus, vitality or detoxification, and none has tested the two together.2,3
Dispensing chain
Who actually fills your prescription
Read the full account
Nobody in the chain is named. Nowhere on the site does VevaRX mention 503A or 503B, the phrase "compounded by", a named, licensed prescriber, a "medical group" or a "doing business as" name. The Terms offer one sentence: the product is "a compounded drug formulation prepared and shipped by an independent, state-licensed compounding pharmacy", which names a category rather than a company. No physician, medical director or advisory name appears anywhere; the About page describes "our dedicated remote team of professionals" and lists no people. What the site does state, and states well, is what a compounded preparation is not: every peptide page carries the line "Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before marketing."
Read on the VevaRX site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published for any peptide. The site's LegitScript certification is genuine and its seal names VevaRX's live domain — but the word "LegitScript" appears in no text anywhere on the site, so a reader can only discover it by inspecting the image. Set against that, VevaRX's disclosure of what compounding means is the strongest among the sellers we review and appears unprompted on every product page. The one place the site reaches for an evidence word, it substitutes a popularity claim: a homepage panel headed "Evidence-based GLP-1 care" explains itself as "custom-formulated compounded medications using ingredients commonly prescribed in medical practice." How commonly an ingredient is prescribed is not evidence about whether it works.
Read on the VevaRX site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
The FAQ enumerates 36 states: Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, Washington, Wisconsin and Wyoming. The Terms say twice that products are available across "the 50 U.S. states". Both statements are on the live site and they cannot both be right; the enumerated list is the more specific one, and it is fourteen states shorter.
Read the full licensing claim
No clinician is named — no prescriber, no medical director, no advisory panel, and no people at all on the About page. The entity is VevaRx LLC. No physical address is published anywhere on the site, although the refund clause instructs customers to send written requests to "our physical mailing address", and the governing-law clause is circular, naming "the state in which VevaRx operates" without ever saying which state that is.
Read on the VevaRX site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- Every peptide page carries, unprompted, the clearest compounding disclosure among the sellers we review: compounded medications are not FDA-approved and the FDA does not verify their safety, effectiveness or quality.
- Its NAD+ education panel is some of the most careful writing we found in this category — it describes the molecule's role in a cell rather than promising the buyer an outcome, and says the aging research is ongoing.
- Its sermorelin page makes no efficacy claim at all, which on this molecule is the only honest position available.
Show 4 more
- Prices are visible before any intake, account or questionnaire, and the sermorelin, NAD+, PT-141 and stack pages each state one figure throughout.
- Its PT-141 page names the outcome the phase 3 trials actually measured.
- Its LegitScript certification is real and points at the live domain.
- No FDA warning letter against VevaRx LLC.
- The glutathione page quotes two prices for one three-month plan: $349 on the card and $267 in the plan and billing text.
- The NAD+ headline promises energy, focus and cellular vitality, which the careful education panel beneath it declines to claim.
- The glutathione claim drops its hedge on the last item and states flatly that the product will reduce inflammation.
Show 5 more
- The stack page adds "focus, and vitality" to the careful NAD+ sentence it borrows, and sells the pair as "Cellular Energy + Detox Support".
- "Evidence-based" is glossed on the homepage as ingredients "commonly prescribed in medical practice", which is popularity, not evidence.
- No pharmacy, no clinician and no physical address is published anywhere — while the refund clause tells customers to write to a mailing address.
- The Terms claim 50-state availability twice; the FAQ enumerates 36.
- The contact page answers "How do I take Semaglutide or Tirzepatide?" with instructions to mix a scoop of a powdered supplement into cold water.
Verdict
The bottom line
Give VevaRX the credit it has earned: it states plainly that compounded medicines are not FDA-approved, its sermorelin page promises nothing it cannot show, and its NAD+ education panel is as careful as anything we read in this category. Then ask it the questions its site does not answer: which pharmacy compounds your prescription, who prescribes it, and where to send a refund request. On glutathione, confirm the price at checkout.
Opens VevaRX's website. A link is not a recommendation to take anything.
The part VevaRX gets right
Most sellers in this market either bury the word "compounded" or never write it. VevaRX puts this at the foot of every peptide page, unprompted:
"Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before marketing."
And its NAD+ education panel is the most careful copy we have read in this category. Watch what it is careful about:
"NAD+ helps support the normal cellular processes involved in converting nutrients into usable energy."
"NAD+ is being studied for its role in age-related cellular processes, though research is ongoing."
Those are claims about what a molecule does inside a cell. They are not claims about what will happen to you. The distinction is the whole ballgame in this category, and almost nobody draws it.
The panel then closes with a line saying the information "is not intended to diagnose, treat, cure, or prevent any disease."
Full analysis — 5 more sectionsAnd then the headline on the same page · What it costs · The stack · One claim that drops the hedge · What is not published
And then the headline on the same page
NAD+ — Support Energy, Focus, & Cellular Vitality
That is a promise to the buyer, in the largest type on the page, sitting a few hundred pixels above a panel that pointedly declines to make it. No completed randomized trial of injected NAD+ in humans supports it. 2
One page, two voices, and the loud one is the one that isn't supported.
What it costs
Every price is on the product page before any intake. Four of the five pages state one figure throughout:
| Peptide | Price on the page |
|---|---|
| Sermorelin, three months | $399 |
| NAD+, three months | $399 |
| PT-141 | $247 a month, or $598 for three months |
| Glutathione, three months | $349 on the card, $267 in the plan and billing text |
| NAD+ & Glutathione Stack, three months | $699, against $748 bought separately |
Glutathione is the exception. The card says $349, and so does the NAD+ and glutathione stack page when it adds up the two separate prices; the "Important Plan Information" and billing text underneath say $267. Confirm the glutathione figure before you pay.
The stack
The newest product pairs the two: the NAD+ & Glutathione Stack, $699 for three months, $49 less than the two plans bought separately. Its education panel mostly keeps the NAD+ page's care. Glutathione "participates in the body's normal antioxidant, detoxification, and immune-supporting processes", and both therapies "are being studied for their roles in healthy aging, though research is ongoing."
One sentence changed on the way over. On the NAD+ page, NAD+ supports the processes "involved in converting nutrients into usable energy." On the stack page, the same sentence ends "into usable energy, focus, and vitality." Those three words move the claim from the cell to the buyer, and the headline above them sells "Cellular Energy + Detox Support". No randomized trial of either injection has measured those outcomes, and none has tested the two together. 2 3
One claim that drops the hedge
VevaRX's glutathione tagline:
"Support cellular detoxification, immune function, healthy aging, and reduce inflammation."
Three hedged items and then a flat physiological assertion. Searched to August 2026, seven randomized records exist for injected glutathione across skin, detoxification, fatigue and energy outcomes, and not one tests injected glutathione on its own. 3 On a site that elsewhere writes so carefully about the limits of what is known, this is the sentence that doesn't belong.
What is not published
No pharmacy. No clinician. No address.
Nothing on the site, not even in the page code, names a compounder or a prescriber. The Terms say the product comes from "an independent, state-licensed compounding pharmacy" — a category, not a company.
The address gap has a practical edge: VevaRX's refund clause tells customers to send written requests to "our physical mailing address", and no page gives one.
Questions
Frequently asked questions
Which price will I actually be charged?
On sermorelin, NAD+, PT-141 and the NAD+ & Glutathione Stack the page states one figure throughout: $399 and $399 for three months, $247 a month or $598 for three months on PT-141, and $699 for three months of the stack. Glutathione's page shows $349 on the card and $267 in the plan and billing text, so confirm that one before paying.
Is the NAD+ claim supported?
The headline is not; the education panel below it does not make one. "Support Energy, Focus, & Cellular Vitality" has no completed randomized trial of injected NAD+ behind it. The panel underneath says only that NAD+ helps support normal cellular processes and that the aging research is ongoing — which is accurate, and is a claim about the molecule rather than about you.
Does VevaRX say its medicines are FDA-approved?
No — it says the opposite, on every peptide page, without being asked. "Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before marketing." That is the clearest disclosure of any seller we review and it deserves saying plainly.
Which pharmacy compounds these, and who prescribes them?
Neither is named, anywhere on the site. The About page describes "our dedicated remote team of professionals" and names no people. No physical address is published either, although the refund clause asks customers to write to one.
Is it available in my state?
The site gives two answers. Its Terms say twice that products are available across the 50 U.S. states; its FAQ enumerates 36. The enumerated list is the more specific of the two and is fourteen states shorter, so check it before ordering.
Does VevaRX hold an FDA warning letter?
No. FDA's warning-letter database has no letter under "VevaRx", "VevaRX", "Veva Rx" or "VevaRx LLC".
Glossary
Key terms
Show definitions
- Compounded medication
- A preparation made by a pharmacy for a specific prescription rather than manufactured under an FDA approval. It has not been reviewed by FDA for safety, effectiveness or quality — which is exactly what VevaRX's own disclosure says.
- Evidence-based
- A claim that a practice is supported by studies of whether it works. It is not the same as a claim that an ingredient is widely prescribed, which is a fact about prescribing habits.
Compare
Others selling what VevaRX sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
- Pallas HealthAlso sells NAD+ (nicotinamide adenine dinucleotide) · 4 of 4 claims match the trials
- ShedAlso sells Sermorelin · 4 of 6 claims match the trials
- CareBareRXAlso sells NAD+ (nicotinamide adenine dinucleotide) · 2 of 4 claims match the trials
- EdenAlso sells Sermorelin · 3 of 6 claims match the trials
Ranked
The lists VevaRX is on
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off VevaRX's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 4 sources
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005; ClinicalTrials.gov intervention "sermorelin" — 27 studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). PubMed search: nicotinamide adenine dinucleotide AND (injection OR subcutaneous) AND randomized controlled trial[pt] — zero records for injected NAD+ in humans. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=nicotinamide+adenine+dinucleotide+AND+injection+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). PubMed search: glutathione[tiab] AND injected route AND (skin OR detoxification OR fatigue OR energy) AND randomized controlled trial[pt] — 7 records, none testing injected glutathione alone; ClinicalTrials.gov injected-route glutathione — 3 studies, in lymphoma, acute liver failure and pneumonia. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=glutathione%5Btiab%5D+AND+randomized+controlled+trial%5Bpt%5D
- Kingsberg SA, Clayton AH, Portman D, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstetrics & Gynecology. https://clinicaltrials.gov/study/NCT02333071
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.